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Clinical Question 
What type of angiotensin blockade is preferred in patients with diabetic nephropathy? 
Evidence-Based Answer 
When used to delay the progression of early nephropathy in patients with type 2 diabetes 
mellitus, angiotensin receptor blockers (ARBs) are not superior to angiotensin-converting 
enzyme (ACE) inhibitors. (Strength of Recommendation: C, multiple randomized controlled 
trials [RCTs]). 
Evidence Summary 
A multicenter, double-blind trial called the Diabetics Exposed to Telmisartan and Enalapril 
(DETAIL) study randomized 250 patients with type 2 diabetes and early nephropathy to receive 
telmisartan (Micardis; 120 persons) or enalapril (Vasotec; 130 persons). The study followed the 
patients for five years. The primary outcome, which was change in glomerular filtration rate 
(GFR) from the baseline value to the last available value during the study period, was not 
significantly different between the two groups. The mean GFR declined by 17.5 mL per min per 
1.73 m2 in the telmisartan group compared with 15.0 mL per min per 1.73 m2 in the enalapril 
group (treatment difference: -2.6 mL per min per 1.73 m2; 95% confidence interval [CI], -7.1 to 
2.0 mL per min per 1.73 m2).1 
An earlier multicenter, double-blind, one-year trial comparing the effects of losartan (Cozaar) 
and enalapril on kidney function randomized 103 patients with type 2 diabetes and early 
nephropathy to receive losartan (52 persons) or enalapril (51 persons). The primary outcome was 
change of urine albumin excretion (UAE) from baseline to week 52. Although UAE decreased in 
both groups, the reduction was not significantly different between the two groups.2 
Most recently, a study on stabilization and regression of albuminuria in Chinese patients with 
type 2 diabetes randomized 42 patients with normal renal function or early nephropathy to 
valsartan (Diovan; 22 persons) or enalapril (20 persons) for one year. The primary outcome was 
the change of UAE from baseline to week 52. The absolute difference in decrease of UAE 
between the two treatment groups was 1 percent, which was not statistically or clinically 
significant. The sample size required for clinical relevance was calculated at 20 patients in each 
group.3 
These are the only trials that have directly compared an angiotensin-II receptor blocker with an 
ACE inhibitor in persons with type 2 diabetes and early nephropathy. In all three studies, the 
patients had an age range of 30 to 80 years, mild to moderate hypertension, and were allowed to 
be on additional antihypertensive agents with the exception of ACE inhibitors, ARBs, and 
dihydropyridine calcium channel blockers. All three studies had sufficient numbers of persons to 
achieve a power of at least 80 percent. 
Adverse events in the ACE inhibitor and ARB groups were similar; however, one study found 
that the ACE inhibitor group was associated with a significantly higher incidence of cough 
(number needed to harm = 7, P = .006). In the DETAIL study, telmisartan and enalapril were 
associated with similar incidence of end-stage renal disease, myocardial infarction, stroke, 
congestive heart failure, and all-cause mortality1; these events were not studied in the other two 
trials.2,3 In other RCTs and systematic reviews, the survival benefit (mainly from cardiovascular 
events) is better substantiated in ACE inhibitors than ARBs.4-8 
Recommendations from Others 
The American Diabetes Association recommends using ACE inhibitors or ARBs for the 
treatment of early nephropathy in patients with type 2 diabetes mellitus, regardless of the 
presence of hypertension, to delay the progression of microalbuminuria.9 
Clinical Commentary 
From an effectiveness standpoint, ARBs have not been shown to be superior to ACE inhibitors 
for prevention of diabetic nephropathy. Because of the availability of generic versions, ACE 
inhibitors have a lower cost and, therefore, should be favored for this indication. In addition to 
managing diabetes, other compelling indications for ACE inhibitors include managing chronic 
kidney disease and congestive heart failure. 
The side effect profile for ACE inhibitors is similar to that of ARBs. However, for reasons that 
are not entirely clear, some patients will develop a cough when taking an ACE inhibitor. In 
general, ARBs should be reserved for use when ACE inhibitors cannot be tolerated because of 
cough. 
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